CN116983340B - Prebiotic microcapsule, preparation method and application - Google Patents
Prebiotic microcapsule, preparation method and application Download PDFInfo
- Publication number
- CN116983340B CN116983340B CN202310794641.8A CN202310794641A CN116983340B CN 116983340 B CN116983340 B CN 116983340B CN 202310794641 A CN202310794641 A CN 202310794641A CN 116983340 B CN116983340 B CN 116983340B
- Authority
- CN
- China
- Prior art keywords
- parts
- water
- mixing
- prebiotic
- phase component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 41
- 239000003094 microcapsule Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 74
- 239000000843 powder Substances 0.000 claims abstract description 31
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 18
- 229920000057 Mannan Polymers 0.000 claims abstract description 18
- 239000010903 husk Substances 0.000 claims abstract description 18
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 18
- 239000000661 sodium alginate Substances 0.000 claims abstract description 18
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 18
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 15
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 15
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 claims abstract description 14
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 13
- 235000019484 Rapeseed oil Nutrition 0.000 claims abstract description 13
- 244000269722 Thea sinensis Species 0.000 claims abstract description 13
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 13
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 13
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 13
- 239000011648 beta-carotene Substances 0.000 claims abstract description 13
- 229960002747 betacarotene Drugs 0.000 claims abstract description 13
- 239000001110 calcium chloride Substances 0.000 claims abstract description 13
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 13
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 13
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 10
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 10
- 206010061218 Inflammation Diseases 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims description 30
- 230000000968 intestinal effect Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 235000019198 oils Nutrition 0.000 claims description 15
- 239000000839 emulsion Substances 0.000 claims description 13
- 241001127637 Plantago Species 0.000 claims description 9
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 claims description 8
- 244000134552 Plantago ovata Species 0.000 claims description 8
- 235000003421 Plantago ovata Nutrition 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000009856 intestinal mucosal lesion Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 abstract description 7
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 7
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 28
- 239000012071 phase Substances 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000001744 histochemical effect Effects 0.000 description 4
- 102000002029 Claudin Human genes 0.000 description 3
- 108050009302 Claudin Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 108010027843 zonulin Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
The invention belongs to the field of prebiotic microcapsules, and discloses a prebiotic microcapsule, a preparation method and application. The raw materials of the prebiotic microcapsule comprise the following components in parts by weight: 2-5 parts of sodium alginate, 0.5-3 parts of tea polyphenol, 1-3 parts of plantain seed husk powder, 1-3 parts of mannans, 1-3 parts of chitosan, 5-10 parts of calcium chloride powder, 200-1500 parts of water, 0.5-3 parts of beta-carotene and 25-150 parts of rapeseed oil. The prebiotic microcapsule disclosed by the invention can effectively improve the problems of intestinal mucosa damage and inflammation.
Description
Technical Field
The invention belongs to the field of prebiotic microcapsules, and particularly relates to a prebiotic microcapsule, a preparation method and application.
Background
The damage of intestinal mucosa causes inflammatory bowel disease, seriously affects the quality of life of people, and even threatens the life of people. The prebiotics comprise dietary fiber, plant polyphenol and the like, can be fermented by specific bacteria in intestinal tracts and generate short-chain fatty acid, thereby playing various roles of resisting inflammation, promoting colon cell proliferation, protecting intestinal mucosa barrier and the like. However, how to combine and apply different prebiotics, especially dietary fibers and polyphenols, to achieve accurate intestinal delivery and optimize the repair effect on intestinal mucosa injury, and still has technical problems.
Therefore, it is currently needed to propose a prebiotic microcapsule, and a preparation method and application thereof.
Disclosure of Invention
The invention aims at overcoming the defects of the prior art, and provides a prebiotic microcapsule, a preparation method and application. The prebiotic microcapsule disclosed by the invention can effectively improve the problems of intestinal mucosa damage and inflammation.
In order to achieve the above object, a first aspect of the present invention provides a prebiotic microcapsule (LFAID), the raw materials of which comprise the following components in parts by weight: 2-5 parts of sodium alginate, 0.5-2 parts of tea polyphenol, 1-3 parts of plantain seed husk powder, 1-3 parts of mannans, 1-3 parts of chitosan, 5-10 parts of calcium chloride powder, 200-1500 parts of water, 0.5-2 parts of beta-carotene and 25-150 parts of rapeseed oil.
According to the invention, preferably, the raw materials of the prebiotic microcapsules comprise the following components in parts by weight: 2.5-3.5 parts of sodium alginate, 0.5-1.5 parts of tea polyphenol, 1.5-2.5 parts of plantain seed husk powder, 1.5-2.5 parts of mannans, 1.5-2.5 parts of chitosan, 6-9 parts of calcium chloride powder, 500-1400 parts of water, 0.5-1.5 parts of beta-carotene and 25-80 parts of rapeseed oil.
According to the invention, preferably, the raw materials of the prebiotic microcapsules comprise the following components in parts by weight: 3 parts of sodium alginate, 1 part of tea polyphenol, 2 parts of plantain seed husk powder, 2 parts of mannans, 2 parts of chitosan, 8 parts of calcium chloride powder, 500-1400 parts of water, 1 part of beta-carotene and 50 parts of rapeseed oil.
The second aspect of the invention provides a preparation method of the prebiotic microcapsule, which comprises the following steps:
S1: mixing and stirring the sodium alginate, the tea polyphenol and a part of the water uniformly to obtain a water phase component I;
S2: uniformly mixing and stirring the Plantago ovata husk powder, the mannans, the chitosan and the calcium chloride powder with the rest of the water, and taking supernatant to obtain a water phase component II;
S3: mixing and stirring the beta-carotene and rapeseed oil uniformly to obtain an oil phase component;
s4: mixing and stirring the water phase component I and the oil phase component uniformly to obtain an oil-water mixed emulsion;
s5: and mixing and solidifying the heated water phase component II and the oil-water mixed emulsion, sucking an oil layer, and centrifuging to obtain the prebiotic microcapsule.
According to the present invention, preferably, in step S1, the ratio of water to sodium alginate is (80-150): 1, a step of;
the temperature of the mixture is 75-85 ℃;
The mixing and stirring are carried out for 3-10min.
According to the present invention, preferably, in step S2, the ratio of water to the mass sum of the psyllium husk powder, the mannans, and the chitosan is (80-120): 1, a step of;
the temperature of the mixture is 95-105 ℃.
According to the present invention, it is preferable that in step S4, the mixing and stirring are performed for a time of 15 to 25 minutes.
According to the present invention, preferably, in step S5, the second aqueous phase component is heated to 75-85 ℃ and then mixed with the oil-water mixed emulsion for solidification;
the mixing and curing time is 0.8-1.5h;
the rotating speed of the centrifugation is 6500-7500r/min, and the time of the centrifugation is 10-20min.
In the invention, as a preferred scheme, the preparation method of the prebiotic microcapsule comprises the following steps:
S1: 3 parts of sodium alginate and water are mixed according to the proportion of 1:100, adding 1 part of tea polyphenol into a mixture of water and sodium alginate under the water bath condition of 80 ℃, mixing and stirring for 5min to obtain a water phase component I;
S2: 2 parts of plantain seed husk powder and water are mixed according to a proportion of 1:100, mixing uniformly; 2 parts of mannan are mixed with water in the ratio 1:100, mixing uniformly; 2 parts of chitosan and water are mixed according to the proportion of 1:100, mixing uniformly; mixing and stirring uniformly the mixture of water and Plantago ovata husk powder, the mixture of water and mannan and the mixture of water and chitosan, adding 8 parts of calcium chloride powder into the mixture, mixing and stirring uniformly, and taking supernatant to obtain a water phase component II;
S3: mixing and stirring 1 part of beta-carotene and rapeseed oil according to a ratio of 1:50 uniformly to obtain an oil phase component;
s4: dropwise adding the water phase component into the oil phase component at normal temperature under the stirring of a magnetic stirrer, and mixing and stirring for 20min to obtain an oil-water mixed emulsion;
s5: and (3) dropwise adding the water phase component heated to 80 ℃ into the oil-water mixed emulsion for mixing and curing for 1h, sucking the oil layer, and centrifuging for 15min at 7000r/min to obtain the prebiotic microcapsule.
The third aspect of the invention provides the use of the prebiotic microcapsule in the manufacture of a medicament for the treatment or alleviation of intestinal mucosal injury.
The fourth aspect of the invention provides the use of the prebiotic microcapsules in the manufacture of a medicament for the treatment or alleviation of intestinal inflammation.
The technical scheme of the invention has the following beneficial effects:
the prebiotic microcapsule of the formula can effectively improve the problems of intestinal mucosa damage and inflammation, and is particularly characterized in that the expression of intestinal canal tight junction protein is promoted, and the intestinal tissue damage is reduced.
Additional features and advantages of the invention will be set forth in the detailed description which follows.
Drawings
The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular descriptions of exemplary embodiments of the invention as illustrated in the accompanying drawings wherein like reference numbers generally represent like parts throughout the exemplary embodiments of the invention.
Fig. 1 (a) is a graph showing the change in body weight (g) of each group of mice in the test example.
FIG. 1 (B) shows a schematic diagram of the intestinal tract tissue structure of mice in each group of test cases ("Histochemical staining" means histochemical staining).
FIG. 1 (C) is a physical plot of colon length for each group of mice in the test case.
FIG. 1 (D) shows a comparison of intestinal inflammation (colon inflammation) for each group of mice in the test case.
FIG. 1 (E) shows a comparison of levels of inflammatory factor (TNF-. Alpha.) in intestinal tissue of mice of each group of test cases.
FIG. 1 (F) shows a comparison of histochemical stained intestinal tissue injury scores (histology score) for groups of mice in the test case.
FIG. 1 (G) shows a comparison of enteritis activity index (DISEASE ACTIVITY index) for each group of mice in the test case.
FIG. 1 (H) shows a comparison of the ZO-1 gene, the OC-claudin gene and the claudin expression gene (wherein RELATIVE GENE expression represents the related gene expression) of each group of mice in the test case.
Detailed Description
Preferred embodiments of the present invention will be described in more detail below. While the preferred embodiments of the present invention are described below, it should be understood that the present invention may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
Example 1
The embodiment provides a prebiotic microcapsule (LFAID), the raw materials of which comprise the following components in parts by weight: 3 parts of sodium alginate, 1 part of tea polyphenol, 2 parts of plantain seed husk powder, 2 parts of mannans, 2 parts of chitosan, 8 parts of calcium chloride powder, 900 parts of water, 1 part of beta-carotene and 50 parts of rapeseed oil.
The preparation method of the prebiotic microcapsule comprises the following steps:
S1: 3 parts of sodium alginate and water are mixed according to the proportion of 1:100, adding 1 part of tea polyphenol into a mixture of water and sodium alginate under the water bath condition of 80 ℃, mixing and stirring for 5min to obtain a water phase component I;
S2: 2 parts of plantain seed husk powder and water are mixed according to a proportion of 1:100, mixing uniformly; 2 parts of mannan are mixed with water in the ratio 1:100, mixing uniformly; 2 parts of chitosan and water are mixed according to the proportion of 1:100, mixing uniformly; mixing and stirring uniformly the mixture of water and Plantago ovata husk powder, the mixture of water and mannan and the mixture of water and chitosan, adding 8 parts of calcium chloride powder into the mixture, mixing and stirring uniformly, and taking supernatant to obtain a water phase component II;
S3: mixing and stirring 1 part of beta-carotene and rapeseed oil according to a ratio of 1:50 uniformly to obtain an oil phase component;
s4: dropwise adding the water phase component into the oil phase component at normal temperature under the stirring of a magnetic stirrer, and mixing and stirring for 20min to obtain an oil-water mixed emulsion;
s5: and (3) dropwise adding the water phase component heated to 80 ℃ into the oil-water mixed emulsion for mixing and curing for 1h, sucking the oil layer, and centrifuging for 15min at 7000r/min to obtain the prebiotic microcapsule.
Test case
The present test example uses the prebiotic microcapsules (LFAID) of example 1 to interfere with the sodium Dextran Sulfate Salt (DSS) induced colon mucosal lesion mouse model, and the specific test method is as follows:
Male KM mice (6-8 weeks old, 20+ -2 g) were acclimatized for 1 week before the experiment, and the mice were kept in a laboratory with a constant temperature of 23+ -2deg.C, a humidity of 50+ -5% and a light-dark cycle of 12 h.
Mice were randomized into four groups including a control group (control) with sterile water treatment, a model group (DSS) with DSS (2%), a test group with DSS (2%) + LFAID (dss+ LFAID), a test group with DSS (2%) +inulin (dss+ lnulin).
After successful modeling of inflammatory bowel disease (inflammatoryboweldisease, IBD) in the experimental mice, 2 groups of mice were fed with the feed containing inulin and LFAID, respectively, for 42 days. Wherein, on day 21 after dietary intervention, the mice of each group except the control group were given 2% (w/v) DSS for 3 consecutive days for the enhancement of the inflammatory bowel disease model.
Mice are sacrificed after the experiment is finished, tissues and organs are collected, colon length of each group of mice is compared, weight change condition and food intake change of the mice are compared, and TNF-alpha level and intestinal tissue structure difference in plasma of the mice are detected.
The test results are shown in FIGS. 1 (A) - (H):
As shown in fig. 1 (a), the weight change of each group of mice is shown. As shown in FIG. 1 (B), the intestinal tract tissue structures of the mice in each group were shown. As shown in FIG. 1 (C), a real plot of colon length was obtained for each group of mice. As shown in fig. 1 (D), intestinal inflammation (colon inflammation) was compared in each group of mice. As shown in FIG. 1 (E), the levels of inflammatory factor (TNF-. Alpha.) in intestinal tissues of each group of mice were compared. As shown in fig. 1 (F), a comparison of histochemical stained intestinal tissue injury scores (histology score) for each group of mice was made. As shown in FIG. 1 (G), the enteritis activity index (DISEASE ACTIVITY index) of each group of mice was compared. As shown in FIG. 1 (H), the comparison of the ZO-1 gene, the OC-claudin gene and the claudin expression gene was performed in each group of mice.
As can be seen from fig. 1 (B), the intestinal tissue structure of mice was significantly improved compared to the DSS (2%) treated model group after LFAID dry prognosis;
As can be seen from fig. 1 (C), (D), (F) and (G), the intestinal injury of mice was significantly improved after LFAID dry prognosis;
as can be seen from fig. 1 (H), after LFAID is performed, the expression of mouse intestinal canal zonulin ZO-1, OC-claudin and claudin is significantly improved, which indicates that LFAID intervention significantly promotes the repair of intestinal barrier and improves DSS-induced intestinal mucosa injury;
As can be seen from fig. 1 (E), the level of inflammatory factor (TNF- α) in the intestinal tissue of mice was significantly reduced after LFAID stem prognosis, indicating that LFAID intervention significantly reduced DSS-induced intestinal inflammation.
The foregoing description of embodiments of the invention has been presented for purposes of illustration and description, and is not intended to be exhaustive or limited to the embodiments disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the various embodiments described.
Claims (8)
1. The prebiotic microcapsule is characterized in that the raw materials of the prebiotic microcapsule consist of the following components in parts by weight: 2-5 parts of sodium alginate, 0.5-2 parts of tea polyphenol, 1-3 parts of plantain seed husk powder, 1-3 parts of mannans, 1-3 parts of chitosan, 5-10 parts of calcium chloride powder, 200-1500 parts of water, 0.5-2 parts of beta-carotene and 25-150 parts of rapeseed oil;
the preparation method of the prebiotic microcapsule comprises the following steps:
S1: mixing and stirring the sodium alginate, the tea polyphenol and a part of the water uniformly to obtain a water phase component I;
In step S1, the ratio of water to sodium alginate is 80-150:1, a step of;
the temperature of the mixture is 75-85 ℃;
Mixing and stirring for 3-10min;
S2: uniformly mixing and stirring the Plantago ovata husk powder, the mannans, the chitosan and the calcium chloride powder with the rest of the water, and taking supernatant to obtain a water phase component II;
In the step S2, the ratio of water to the mass sum of the Plantago ovata husk powder, the mannans and the chitosan is 80-120:1, a step of;
the temperature of the mixture is 95-105 ℃;
S3: mixing and stirring the beta-carotene and rapeseed oil uniformly to obtain an oil phase component;
s4: mixing and stirring the water phase component I and the oil phase component uniformly to obtain an oil-water mixed emulsion;
S5: mixing and solidifying the heated water phase component II and the oil-water mixed emulsion, sucking an oil layer, and centrifuging to obtain the prebiotic microcapsule;
in the step S5, heating the second water phase component to 75-85 ℃ and then mixing and solidifying with the oil-water mixed emulsion;
the mixing and curing time is 0.8-1.5h;
the rotating speed of the centrifugation is 6500-7500r/min, and the time of the centrifugation is 10-20min.
2. The prebiotic microcapsule according to claim 1, wherein the raw materials of the prebiotic microcapsule consist of the following components in parts by weight: 2.5-3.5 parts of sodium alginate, 0.5-1.5 parts of tea polyphenol, 1.5-2.5 parts of plantain seed husk powder, 1.5-2.5 parts of mannans, 1.5-2.5 parts of chitosan, 6-9 parts of calcium chloride powder, 500-1400 parts of water, 0.5-1.5 parts of beta-carotene and 25-80 parts of rapeseed oil.
3. The prebiotic microcapsule according to claim 1, wherein the raw materials of the prebiotic microcapsule consist of the following components in parts by weight: 3 parts of sodium alginate, 1 part of tea polyphenol, 2 parts of plantain seed husk powder, 2 parts of mannans, 2 parts of chitosan, 8 parts of calcium chloride powder, 500-1400 parts of water, 1 part of beta-carotene and 50 parts of rapeseed oil.
4. The prebiotic microcapsule according to claim 1, wherein in step S4, the mixing and stirring is carried out for a period of 15-25min.
5. A method of preparing a prebiotic microcapsule according to any of claims 1 to 4, comprising the steps of:
S1: mixing and stirring the sodium alginate, the tea polyphenol and a part of the water uniformly to obtain a water phase component I;
In step S1, the ratio of water to sodium alginate is 80-150:1, a step of;
the temperature of the mixture is 75-85 ℃;
Mixing and stirring for 3-10min;
S2: uniformly mixing and stirring the Plantago ovata husk powder, the mannans, the chitosan and the calcium chloride powder with the rest of the water, and taking supernatant to obtain a water phase component II;
In the step S2, the ratio of water to the mass sum of the Plantago ovata husk powder, the mannans and the chitosan is 80-120:1, a step of;
the temperature of the mixture is 95-105 ℃;
S3: mixing and stirring the beta-carotene and rapeseed oil uniformly to obtain an oil phase component;
s4: mixing and stirring the water phase component I and the oil phase component uniformly to obtain an oil-water mixed emulsion;
S5: mixing and solidifying the heated water phase component II and the oil-water mixed emulsion, sucking an oil layer, and centrifuging to obtain the prebiotic microcapsule;
in the step S5, heating the second water phase component to 75-85 ℃ and then mixing and solidifying with the oil-water mixed emulsion;
the mixing and curing time is 0.8-1.5h;
the rotating speed of the centrifugation is 6500-7500r/min, and the time of the centrifugation is 10-20min.
6. The method for preparing prebiotic microcapsules of claim 5, wherein in step S4, the mixing and stirring are performed for a period of 15-25min.
7. Use of a prebiotic microcapsule according to any of claims 1-4 in the manufacture of a medicament for the treatment or alleviation of intestinal mucosal lesions.
8. Use of a prebiotic microcapsule according to any of claims 1-4 in the manufacture of a medicament for the treatment or alleviation of intestinal inflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310794641.8A CN116983340B (en) | 2023-06-30 | 2023-06-30 | Prebiotic microcapsule, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310794641.8A CN116983340B (en) | 2023-06-30 | 2023-06-30 | Prebiotic microcapsule, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116983340A CN116983340A (en) | 2023-11-03 |
| CN116983340B true CN116983340B (en) | 2024-10-22 |
Family
ID=88531092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310794641.8A Active CN116983340B (en) | 2023-06-30 | 2023-06-30 | Prebiotic microcapsule, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116983340B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105534951A (en) * | 2016-01-08 | 2016-05-04 | 魏永刚 | Synbiotic microcapsules and preparing method and application thereof |
| CN115969957A (en) * | 2022-12-21 | 2023-04-18 | 浙江佰穗莱生命健康科技有限公司 | Compound probiotic preparation for inflammatory bowel diseases and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112315943B (en) * | 2020-11-19 | 2022-02-25 | 广东海洋大学 | Asiaticoside-chitosan-sodium alginate microspheres, preparation method and application thereof |
| CN117941834A (en) * | 2024-02-04 | 2024-04-30 | 成都大学 | Probiotic microcapsule and preparation method thereof |
-
2023
- 2023-06-30 CN CN202310794641.8A patent/CN116983340B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105534951A (en) * | 2016-01-08 | 2016-05-04 | 魏永刚 | Synbiotic microcapsules and preparing method and application thereof |
| CN115969957A (en) * | 2022-12-21 | 2023-04-18 | 浙江佰穗莱生命健康科技有限公司 | Compound probiotic preparation for inflammatory bowel diseases and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116983340A (en) | 2023-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2697670C9 (en) | Pharmaceutical composition containing silybin and radix puerariae extract | |
| CN104800819B (en) | Traditional Chinese medicine preparation for treating fowl plague | |
| CN116983340B (en) | Prebiotic microcapsule, preparation method and application | |
| CN114632101A (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound for treating obesity and related syndromes as well as preparation method and application thereof | |
| CN103494921B (en) | Traditional Chinese medicinal paper and manufacturing method thereof | |
| CN102961447B (en) | Traditional Chinese medicine composition for promoting egg laying performance of laying hen in middle and later periods and preparation method thereof | |
| CN111617200B (en) | Traditional Chinese medicine preparation for treating and preventing pulmonary hypertension of broiler chicken and preparation method thereof | |
| CN109566807A (en) | Selenium-enriched vine tea and its processing method | |
| CN114886961A (en) | Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof | |
| CN113117036A (en) | A medicine containing green tea extract for treating fatty liver and its preparation method | |
| CN110327340A (en) | Pefloxacin treats and prevents the purposes in high blood cholesterol drug or atherosclerosis drug in preparation | |
| CN115919934B (en) | Peony active substance with effect of inhibiting prostatic hyperplasia, extraction method and application | |
| CN112316072B (en) | Traditional Chinese medicine composition for preventing and treating cold of poultry in autumn and winter and preparation method thereof | |
| CN110564641B (en) | Complex microbial inoculum fermentation product and application thereof as pholcodine synergist | |
| CN107661362A (en) | A kind of red hip nursing ointment and preparation method thereof | |
| CN108740267A (en) | A kind of production method of health care preserved fruit | |
| CN109966164A (en) | A kind of antibacterial blast conditioning liquid of pet hair and preparation method thereof | |
| CN116549430A (en) | Linoleic acid preparation and application thereof in preparation of acute lung injury treatment drugs | |
| CN103071026B (en) | Animal traditional Chinese medicine for treating high fever and preparation method of injection solution thereof | |
| CN105395574A (en) | Medicinal and edible compound squalene and fish oil soft capsule for preventing and treating cardiovascular and cerebtovascular disease | |
| CN116617323A (en) | Preparation for soothing liver and improving nutrition metabolism of poultry and preparation method thereof | |
| CN104288172B (en) | Prevent and treat composition of poultry inclusion body hepatitis and preparation method thereof | |
| CN104257697B (en) | It is a kind of to prevent or the careless composition of silkworm for the treatment of breathing problem and its application | |
| CN105194237A (en) | Composition for treating lymphoma and preparation method of composition | |
| CN110025773A (en) | A kind of pharmaceutical composition and preparation method thereof for treating dog pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |